Navigation Links
Nephros Reports 2011 Fourth Quarter and Full Year Financial Results
Date:3/22/2012

market and other addressable markets for the ultrafiltration product line.  These are the products Nephros has available for sale today, and we are looking to leverage the field studies we have performed which demonstrate the value of these products.  Observational studies have shown a significant reduction in required erythropoietin dosing when the Nephros DSU is utilized during dialysis therapy. In a separate study involving two major U.S. hospitals, the Nephros DSU system was shown to be effective in reducing waterborne Legionella bacteria to undetectable levels, an effect which was sustained for the 3-month study period.  We believe that market forces including more stringent standards for dialysis water purity from the Association for the Advancement of Medical Instruments (AAMI), bundling of dialysis reimbursement payments, and CMS initiatives which relate hospital reimbursement rates to infection control compliance can provide positive momentum for increased adoption Nephros ultrafiltration products. 

During 2011, Nephros completed the initial milestones under the joint collaboration agreement with STERIS Corp. (NYSE: STE) and anticipates completion of the final milestones under the agreement during 2012.  The remaining milestones, if met, would result in aggregate payments to Nephros of $60,000.

In response to a Request For Information (RFI) from the U.S. Army, Nephros submitted its UF-40 ultrafilter for consideration as part of the standard issue hydration pack for soldiers in the field.  Nephros has been informed by the U.S. Army Public Health Command that its UF-40 filter has been validated to meet the military's NSF P248 standard for emergency military operations as a microbiological water purifier.  Nephros believes that its UF-40 filter is the only stand-alone filter to date to have met the performance criteria of the NSF P248 standard without secondary disinfection steps.  The Army has not to date
'/>"/>

SOURCE Nephros, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Nephros Completes Pivotal U.S. Clinical Trial for its Hemodiafiltration Products
2. Nephros Reports 2009 Third Quarter Financial Results
3. Nephros Signs Canadian Distribution Agreement with Bellco Health Care Inc.
4. Nephros Signs Development Agreement with STERIS
5. Nephros Reports 2010 First Quarter Financial Results
6. Nephros and AmeriWater Announce Dual Stage Ultrafilters to be a Standard Component of MRO Series Water Treatment Systems
7. Nephros Receives Formal Response from FDA for 510(k) Application for Hemodiafiltration System
8. Nephros Reports 2010 Second Quarter Financial Results
9. Nephros Completes Bridge Financing and Announces Stockholder Rights Offering
10. Nephros Reports 2010 Third Quarter Financial Results
11. Nephros Rights Offering Registration Statement Declared Effective
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... wearable injector slightly larger than an Oreo cookie may soon ... drugs in the large doses required to treat a wide ... genetic disorders.  An emerging biologic drugs market ... analysts.   Many of these drugs will require a new type ...
(Date:1/14/2014)... , Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ... the fourth quarter of 2013 on Monday, February 3, 2014. ... after the close of trading. (Logo: ... to discuss the operating highlights and financial results for the ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... BEIJING, June 14, 2011 /PRNewswire-Asia-FirstCall/ -- China Medical Technologies, ... leading China-based advanced in-vitro diagnostic ("IVD") company, today announced ... Mr. Xiaodong Wu, Chairman and Chief Executive Officer of ... of the Company,s American Depositary Shares ("ADSs") in the ...
... June 13, 2011 Tengion, Inc. (Nasdaq: ... trial of the Company,s lead clinical product candidate, the ... a urinary diversion following bladder removal (cystectomy). Tengion is ... approach as part of its ongoing clinical trial of ...
Cached Medicine Technology:China Medical Technologies Announces the Purchase of its ADSs by Chengxuan in the Open Market 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 2Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 3Tengion Provides Update on Neo-Urinary Conduit Clinical Trial 4
(Date:4/24/2014)... of prescription opioid overdose deaths was outlined yesterday in ... leaders of agencies in the U.S. Department of Health ... care providers to expand their use of medications to ... a number of misperceptions that have limited access to ... medications can be used in combination with behavior therapies ...
(Date:4/24/2014)... has been awarded one of 30 grants from the ... Academic Participating Site in its new National Clinical ... select groups of investigators charged with distributing resources in ... NCTN grant system reflects recommendations from a 2010 ... achieve four goals:, Faster design, launch, and ...
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Cancer Center researchers say clinical trials for a ... (AML) are very promising. Patients treated with CPX-351, ... daunorubicin, are showing better responses than patients treated ... , "Acute myeloid leukemia is an aggressive blood ... especially in older patients," explained Jeffrey Lancet, M.D., ...
(Date:4/23/2014)... 2014 The American Society for Radiation Oncology (ASTRO) ... Postoperative Radiation Therapy for Endometrial Cancer: An ASTRO ... radiation therapy in the treatment of endometrial cancer. ... May-June 2014 issue of Practical Radiation Oncology ... ASTRO. The full-length guideline is available as an ...
Breaking Medicine News(10 mins):Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 2Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 3Health News:HHS leaders call for expanded use of medications to combat opioid overdose epidemic 4Health News:Dartmouth awarded lead role in NCI clinical trials network 2Health News:Dartmouth awarded lead role in NCI clinical trials network 3Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3
... Delhi: The common cold may cause uncommon ailments if neglected, ... common cold because we have always thought it is harmless. ... left untreated. It could also negatively impact vision or cause ... is a surge in cases of chronic sinusitis because of ...
... the heart in their mouth when they read this bit. Genes ... attack have finally been identified by scientists. ,The ... of Britons carry a particular gene which doubles their chances of ... the form of making healthy lifestyle choices that may help cut ...
... While the field of transplantation is quite young, substantial advancements ... supply of organs and the demand for them. The ... system through a point system based primarily on wait time, ... occurs, the kidney is offered to the person at the ...
... risk for alcohol dependence are more likely to choose a ... University School of Medicine in St. Louis. That doesn't ... problem drinkers. ,Alcoholism is more common among ... isn't as common as it might be. The researchers found ...
... of the New York state government has lashed out at ... as a shameful "chamber of filth, decay, indifference and danger." ... the agency has filed a suit in the federal court ... patients are subjected to overcrowded conditions, physical abuse and unnecessary ...
... the despicable practice of female feticide increased in India, there ... ,Five years ago the Indian Medical Association had ... aiding female feticide. No support would be extended to practitioners ... ,The Indian authorities are wrestling with the problem, and here ...
Cached Medicine News:Health News:A Cold Shoulder to Cold - At Your Risk 2Health News:The DNA That Spells Double Risk of Heart Attack 2Health News:Who Receives a Kidney Transplant First? 2Health News:Spouse may "drive You to Drink" but also can Protect You from Alcohol 2Health News:Suit Filed Against Horrors of Psychiatric Ward in New York Hospital 2Health News:Now Sex Determination of Fetuses in Six Weeks in UK 2
... Single Use linear stapler with ... Auto Suture™ PREMIUM POLY CS™-57 disposable ... creation of a temporary opening, such ... cesarean section, or when transecting muscle ...
... Use reloadable linear stapler ... (DST™) titanium staples., ... Reloadable staplers has application ... and thoracic surgical procedures ...
... reloadable linear stapler for resection, transection and ... Suture™ MULTIFIRE GIA™ 60 and 80 single ... and 80 single use loading units and ... single use surgical stapler with MULTIFIRE SGIA™ ...
... With Titanium Staples for use with PI™ ... ,The PI™ disposable stapler is designed ... of normal, healthy internal tissues. The instrument ... staggered row, when using the 30 VASCULAR ...
Medicine Products: